Axsome Therapeutics Announces Proposed Public Offering of Common Stock
June 27, 2023 20:24 ET
|
Axsome Therapeutics, Inc.
NEW YORK, June 27, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (“Axsome” or the “Company”), a biopharmaceutical company developing novel therapies for the management of central...
Axsome Therapeutics to Present New Sunosi® Data at SLEEP 2023
June 01, 2023 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, June 01, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Axsome Therapeutics to Present Data and Post-Hoc Analyses on Auvelity® and Sunosi® at the 2023 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
May 30, 2023 07:00 ET
|
Axsome Therapeutics, Inc.
Data on Auvelity demonstrating improved functioning in major depressive disorder Data on Sunosi demonstrating improved cognitive function in patients with excessive daytime sleepiness associated with...
Axsome Therapeutics Reports First Quarter 2023 Financial Results and Corporate Update
May 08, 2023 07:00 ET
|
Axsome Therapeutics, Inc.
Auvelity® 1Q 2023 net product sales of $15.7 million Total 1Q 2023 net product sales of $28.6 million Total 1Q 2023 revenue of $94.6 million, including Sunosi® ex-U.S. license agreement upfront...
Axsome Therapeutics to Present at the Bank of America Securities 2023 Healthcare Conference
May 03, 2023 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, May 03, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Axsome Therapeutics Joins Mental Health America and the State of New York to Raise Awareness of Mental Health During May is Mental Health Month
May 01, 2023 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, May 01, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Axsome Therapeutics to Present Five Abstracts Including New Data from the Positive SHARP Study of SUNOSI® (solriamfetol) in Participants with Cognitive Impairment with Excessive Daytime Sleepiness in Obstructive Sleep Apnea at the 2023 American Academy of Neurology (AAN) Annual Meeting
April 21, 2023 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, April 21, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Axsome Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference
April 14, 2023 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, April 14, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Axsome Therapeutics to Report First Quarter 2023 Financial Results on May 8
April 13, 2023 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, April 13, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Axsome Therapeutics to Present at Cowen’s 43rd Annual Health Care Conference
March 01, 2023 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...